ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Clinical trial NCT04578613 · UNKNOWN

Trial details

NCT number: NCT04578613
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2021-01-08
Primary completion: 2024-12-30
Enrollment: 218

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.